PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18239149-0	2008	A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells.	Rosiglitazone	45-58	interferon gamma	Homo sapiens	105-121	
11934839-7	2002	Pretreatment of cells with well-established PPARalpha (WY14643 or fenofibrate) or PPARgamma (BRL49653/rosiglitazone or pioglitazone) activators reduced anti-CD3-induced IFNgamma secretion in a concentration-dependent manner.	Rosiglitazone	102-115	interferon gamma	Homo sapiens	169-177	
18291365-10	2008	Given the pivotal role of IFNgamma-induced chemokines in Th1-mediated allograft rejection, these preliminary results suggest that the combined effects of immunosuppressive agents and rosiglitazone could be potentially beneficial to patients receiving heart transplants.	Rosiglitazone	183-196	interferon gamma	Homo sapiens	26-34	
17445473-10	2007	CONCLUSION: Rosiglitazone could regulate the balance of IFN-gamma and IL-4 through effect on the expression of T-bet mRNA and GATA-3 mRNA.	Rosiglitazone	12-25	interferon gamma	Homo sapiens	56-65	
16303841-9	2006	Treatment of all cell types with the PPARgamma agonist, rosiglitazone, dose-dependently (0.1-10 microm) suppressed IFNgamma- plus TNFalpha-induced CXCL10 release.	Rosiglitazone	56-69	interferon gamma	Homo sapiens	115-123	
17042679-3	2006	In this study, we examine the effects of the glucocorticoid, dexamethasone, and the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, rosiglitazone on the expression of interferon (IFN)-gamma (T(H)1) and interleukin (IL)-4 (T(H)2) by activated peripheral CD4(+) and CD8(+) lymphocytes in patients with HT (n = 10) and healthy control subjects (n = 12).	Rosiglitazone	154-167	interferon gamma	Homo sapiens	189-211	
17042679-7	2006	A dose-dependent inhibition of IFN-gamma expression was seen with dexamethasone and rosiglitazone.	Rosiglitazone	84-97	interferon gamma	Homo sapiens	31-40	
17042679-8	2006	Inhibition of CD4(+) and CD8(+) IFN-gamma expression with both dexamethasone and rosiglitazone was greater in control subjects than in patients (p < 0.05).	Rosiglitazone	81-94	interferon gamma	Homo sapiens	32-41	
16410460-6	2006	In contrast, rosiglitazone significantly reduced CD4-lymphocyte content as well as macrophage HLA-DR expression in the shoulder region, reflecting less inflammatory activation of these cells by lymphocyte interferon-gamma.	Rosiglitazone	13-26	interferon gamma	Homo sapiens	205-221	
23286943-6	2013	Patients treated with rosiglitazone demonstrated significant (P < 0 03) down-regulation of islet-specific T cell responses, although no change in response to tetanus, a significant decrease (P < 0 05) in IFN-gamma production and significantly (P < 0 001) increased levels of adiponectin compared to glyburide-treated patients.	Rosiglitazone	22-35	interferon gamma	Homo sapiens	210-219	
34170488-4	2022	We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFNgamma, TNFalpha, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFNgamma/TNFalpha-dependent signaling in human cardiomyocytes associated with chemokine release.	Rosiglitazone	32-35	interferon gamma	Homo sapiens	83-91	
34170488-8	2022	In human cardiomyocytes, RGZ impaired IFNgamma/TNFalpha signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release.	Rosiglitazone	25-28	interferon gamma	Homo sapiens	38-46	
23707273-8	2013	Direct stimulation of peritoneal macrophages with rosiglitazone also increased HO-1 induction in the presence of lipopolysaccharide/interferon-gamma.	Rosiglitazone	50-63	interferon gamma	Homo sapiens	132-148	
22982856-4	2012	Rosiglitazone inhibited GVHD-induced increases in serum levels of tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-6, and IL-12, and the GVHD-induced decreases in transforming growth factor-beta and IL-10.	Rosiglitazone	0-13	interferon gamma	Homo sapiens	95-111	
21490083-5	2011	In addition, the direct effect of rosiglitazone was evaluated in peritoneal macrophages activated with interferon-gamma.	Rosiglitazone	34-47	interferon gamma	Homo sapiens	103-119	
21490083-8	2011	In peritoneal macrophages, rosiglitazone down-regulated interferon-gamma-induced gene expression of cyclooxygenase-2 and inducible nitric oxide synthase and attenuated the chemotactic response to monocyte chemotactic protein-1.	Rosiglitazone	27-40	interferon gamma	Homo sapiens	56-72	
19896472-5	2010	Both KR62980 and rosiglitazone suppressed IFNgamma production in a dose-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980.	Rosiglitazone	17-30	interferon gamma	Homo sapiens	42-50	
19276231-8	2009	Treating all cell types with the PPARgamma agonist, rosiglitazone, or pioglitazone, the IFNgamma plus TNFalpha-induced CXCL9 and CXCL11 release was dose dependently (0.1-20 microm) suppressed.	Rosiglitazone	52-65	interferon gamma	Homo sapiens	88-96